Protection by U-50,488H against beta-chlornaltrexamine antagonism of nitrous oxide antinociception in mice

Brain Res. 1991 May 17;549(1):162-4. doi: 10.1016/0006-8993(91)90615-3.

Abstract

Nitrous oxide antinociception in the abdominal constriction test was significantly reduced in mice pretreated intracerebroventricularly (i.c.v.) with beta-chlornaltrexamine (beta-CNA). However, this antagonism was reversed when the beta-CNA was co-administered i.c.v. with the kappa-opioid ligand U-50,488H but not the mu-opioid ligand CTOP. These findings further demonstrate that nitrous oxide antinociception in the mouse abdominal constriction paradigm is mediated by kappa- but not mu-opioid receptors.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Analgesia*
  • Analgesics / pharmacology*
  • Animals
  • Fentanyl / analogs & derivatives
  • Fentanyl / pharmacology
  • Male
  • Mice
  • Mice, Inbred ICR
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology*
  • Nitrous Oxide / antagonists & inhibitors
  • Nitrous Oxide / pharmacology*
  • Pain / physiopathology*
  • Pyrrolidines / pharmacology*
  • Sufentanil

Substances

  • Analgesics
  • Narcotic Antagonists
  • Pyrrolidines
  • Naltrexone
  • chlornaltrexamine
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Sufentanil
  • Nitrous Oxide
  • Fentanyl